Latest Biologic Stories
Drug Developers will Rely on Head-to-Head Clinical Trial Data Against Current Therapies to be Poised to Compete in the Increasingly Crowded TNF-alpha-Refractory Space BURLINGTON, Mass., Nov.
DALLAS, November 3, 2014 /PRNewswire/ -- According to the new market research report The "Single Use Bioreactor Market by Product Type (Recombinant Proteins, Monoclonal
Funding round for development of leading bone growth regeneration medicine protein EDISON, N.J., Nov.
PROVIDENCE, R.I., Oct.
BEIJING, Oct. 30, 2014 /PRNewswire/ -- China Biologic Products, Inc.
Payers Employ a Variety of Cost-Control Measures to Manage the Utilization of Premium-Priced RA Agents, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct.
Launches discussion about the future of biosimilars in Italy ROME, Oct.
Expands rHuPH20 Production SAN DIEGO, Oct. 20, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S.
- Withering but not falling off, as a blossom that persists on a twig after flowering.